Alison Elzayed
Business & Finance Writer | StockScope
James Hardie Industries (ASX: JHX) has delivered a 44% increase in quarterly adjusted EBITDA despite continued weakness in the US housing market. Its latest results, released on 6 November 2026 Australian time, also include an upgraded annual free cash flow target exceeding US$650 million.
The stronger performance raises a critical question: can James Hardie sustain its expanding margins while reducing the substantial debt associated with its AZEK acquisition?
James Hardie's results for the quarter ended 30 September 2026 demonstrate improving profitability across its building products operations.
Siding & Trim revenue increased 15% to US$880.3 million, supported by higher fibre cement volumes, favourable pricing and market-share gains against competing materials.
Deck, Rail & Accessories revenue climbed 51% to US$387 million, reflecting stronger customer demand, improved distribution and initial orders through Boise Cascade.
Net income from continuing operations reached US$149.8 million, reversing a US$64.3 million loss in the comparable quarter.
However, adjusted EBITDA excludes certain expenses, including share-based compensation under revised FY27 definitions. Lower acquisition-related expenses also benefited reported profitability.
These distinctions matter when assessing how much of the improvement represents sustainable operating performance.
The most significant development is James Hardie's improved cash generation.
First-half operating cash flow reached US$693.7 million, supporting US$535.4 million in free cash flow after US$158.3 million in capital expenditure. These figures include discontinued operations.
The company repaid US$111 million of term-loan debt during the quarter, although substantial borrowings remain following the AZEK acquisition.
Its balance sheet also carries significant acquired intangible assets and asbestos-related liabilities.
We think stronger cash generation improves the financial outlook, but valuation remains sensitive to financing costs, future earnings and the sustainability of current margins.
The market must also distinguish genuine organic growth from acquisition-related contributions and temporary working capital benefits.
Without a consistently verified current equity valuation, a precise earnings multiple would risk overstating the attractiveness of the business.
James Hardie is expanding distribution, increasing product adoption and integrating AZEK's decking portfolio with its established fibre cement operations.
Management is also pursuing the €840 million sale of its European Fermacell operations to Holcim, with completion expected during the first half of calendar 2027.
Approximately US$600 million of anticipated proceeds is intended for debt repayment.
Meanwhile, previously announced facility closures in California and South Carolina are expected to generate approximately US$25 million in annualised FY27 savings.
These initiatives could improve operating efficiency and accelerate debt reduction, although the European transaction remains subject to completion.
We think James Hardie's established brands, distribution network and product differentiation provide meaningful competitive advantages. The latest results demonstrate improving operating performance and substantially stronger free cash flow, strengthening the case for continued debt reduction. However, the business remains exposed to weak US construction activity, acquisition integration costs and considerable financial obligations. Its valuation requires sustainable earnings rather than acquisition-driven growth alone. Our assessment is cautiously constructive on business fundamentals, but continued margin resilience, organic growth and declining leverage are essential to support market expectations.
Management expects third-quarter FY27 adjusted EBITDA of US$298 million to US$320 million, reflecting seasonal weakness, higher freight costs and challenging market conditions.
Full-year adjusted EBITDA guidance remains US$1.446 billion to US$1.534 billion.
The company is targeting net leverage below 2.0 times adjusted EBITDA by the end of the second quarter of FY28, supported by cash generation and anticipated European divestiture proceeds.
For shareholders, the next results will test whether James Hardie's strong first-half performance represents sustainable improvement or whether margins face renewed pressure.
The decisive question is whether its enlarged building products platform can consistently convert market-share gains into profitable growth, stronger cash flow and a healthier balance sheet.
Alison Elzayed is an experienced business and financial writer with more than 10 years of experience in the publishing industry, having previously worked as an author with Bloomsbury Publishing, specialising in business and finance. Throughout her career, Alison has developed a strong understanding of financial markets, corporate developments, economic trends and investment-related topics. Her background in financial publishing has equipped her with the ability to research complex subjects and communicate them in a clear, accurate and engaging manner.
Australian equities: what moved the ASX 200? Australian shares finished lower on Friday, 6 November, as the technology-led sell-off on Wall Street spread across global markets. The ASX 200...
Mark Elzayed•
Epiminder Limited ASX: EPI has expanded the US market for its epilepsy monitoring technology following a significant regulatory clearance, strengthening its commercial prospects ahead of a p...
Danny Aad•
A 38-metre gold intersection grading 2.1 grams per tonne has given Asara Resources Limited ASX: AS1 an encouraging exploration result beyond its established Massan deposit in Guinea. The dis...
Alison Elzayed•
Alvo Minerals Limited ASX: ALV has extended rare earth mineralisation approximately 2 kilometres beyond previously tested areas at its Boa Vista prospect in Brazil, strengthening the explora...
Alison Elzayed•
Avenira Limited ASX: AEV has reached a significant financing milestone, with its $48.9 million rights issue providing fresh capital to advance the Wonarah Phosphate Project in the Northern T...
Alison Elzayed•
Mayne Pharma Group Limited ASX: MYX is taking a decisive step towards becoming a US-focused pharmaceutical company, agreeing to sell its international operations for $55.5 million. The tran...
Danny Aad•